Recent News on Cryptocurrency, Blockchain, and Finance | Yellow

Blockchain analysts have identified a pattern of suspiciously timed high-leverage trades on the Hyperliquid platform that netted millions in profits.

Pi Network faces intensifying scrutiny over its centralization issues as data reveals the core team controls 82.8 billion of the 100 billion total Pi Coin supply, while operating with only 43 nodes and introducing AI into its KYC process.

The cryptocurrency XRP maintains its position above the crucial $2 threshold despite suffering a 22% price correction and seeing a precipitous drop in active users as long-term holders refuse to sell.

Recent blockchain data indicates Bitcoin miners have significantly increased their cryptocurrency transfers to exchanges following price declines, potentially signaling additional selling pressure in the market.

SEC has extended its timeline to decide on several cryptocurrency exchange-traded funds including XRP, Solana, Litecoin, and Dogecoin, pushing decisions to May amid leadership transition.

On-chain analytics initially misattributed a significant 30,000 ETH transaction to the Ethereum Foundation, sparking liquidation concerns that were later corrected upon further investigation by crypto intelligence firms.

Industry leaders including Ripple CTO David Schwartz and "Rich Dad Poor Dad" author Robert Kiyosaki view Bitcoin's recent price slump as a strategic buying opportunity despite mounting bearish indicators.

AI and DeFi-related tokens like neur.sh (NEUR) and Rivalz Network (RIZ) are seeing increased engagement as blockchain-based AI solutions gain traction.

Bitcoin has experienced a significant 27% pullback from its all-time high, prompting industry experts to compare current market conditions to previous bull cycles while offering divergent predictions on what comes next.

Arbitrum's parent company launches a strategic token buyback initiative to counter an 85% price decline and offset an impending token unlock event, drawing mixed reactions from market analysts who question its long-term effectiveness.